Establishment of novel CTL inducing vaccine by glycan modification
Project/Area Number |
23501290
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Tumor immunology
|
Research Institution | Jikei University School of Medicine |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
SAITO Saburo 東京慈恵会医科大学, 医学部, 准教授 (10186934)
|
Project Period (FY) |
2011-04-28 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 細胞免疫 / 抗原提示 / 糖鎖 / CTL / 腫瘍免疫 / ワクチン |
Outline of Final Research Achievements |
An cationic lipid based adjuvant for inducing cytotoxic T cells (CTL) with protein antigens was prepared and developed to give strong CTL inducing activities by immunizing chicken Ovalbumin (OVA) protein as a model antigen. OVA proteins were expressed and purified in E.Coli and human mammalian cells, examined CTL inducing activities, and the strongest activity was observed with chicken derived antigen, followed by human cells and E.coli in this order. When the protein antigens were expressed in human cell lines, the modification of glycan structures by addition of glycan synthesis inhibitor increased the CTL inducing activity of antigens with cationic adjuvants.
|
Report
(5 results)
Research Products
(1 results)